An anti-WSSV and/or TSV nucleic acid drug, the active ingredients of which are five nucleic acids whose nucleotide sequences are sequence 1, sequence 2, sequence 3, sequence 4 and sequence 5 in the sequence list, respectively. The nucleic acid drug of the present invention has no toxic or side effect or drug tolerance, and can directly kill WSSV and/or TSV with fine antiviral effect and no drug residues.
